In parallel with this study, a pancancer analysis of 9652 tumor patients in the TCGA cohort showed that high expression of IGF2BP3 was strongly associated with poor prognosis (P < 0.001, Fig. 1o). This evidence concerns the gene IGF2BP3 and neoplasm.